6.24.08
|
(June 24, 2008; Leawood, KS): Madeira Therapeutics, a new drug-development company specializing in pediatric pharmaceuticals, has announced the addition of a notable pharmaceutical industry veteran to its Board of Advisors.
According to Madeira CEO Peter S. Joiner, J. Lyle Bootman, PhD, ScD, Dean of the University of Arizona College of Pharmacy will take an active role in the direction of the company.
Dr. J. Lyle Bootman is professor of pharmacy, medicine and public health, and a Fellow of several professional associations including the American Pharmacists Association, American Association of Pharmaceutical Scientists and the American College of Apothecaries. He is the author of Principles of Pharmacoeconomics and the founding and executive director of the University of Arizona Center for Health Outcomes and PharmacoEconomic (HOPE) Research, one of the first such centers in the world. He is former president of the American Pharmacists Association and President Emeritus of the Pharmacy Therapeutics Society.
Dr. Bootman recently received the 2008 Remington Honor Medal, widely considered the profession’s highest honor.
“This is a significant step in the growth and development of Madeira,” stated Pete Joiner, CEO, Madeira Therapeutics. “Our strategy focuses on the reformulation of pediatric pharmaceuticals for appropriate dosage levels in children. Dr. Bootman is a renowned expert—his knowledge and guidance will serve us well. It is an honor to have him join our Board of Advisors.” |
